Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Cash & Equivalents (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of Cash & Equivalents data on record, last reported at $84.3 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 4.73% year-over-year to $84.3 million; the TTM value through Sep 2025 reached $84.3 million, down 4.73%, while the annual FY2024 figure was $83.0 million, 10.65% down from the prior year.
  • Cash & Equivalents reached $84.3 million in Q3 2025 per UTMD's latest filing, up from $82.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $93.8 million in Q1 2024 and bottomed at $56.0 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $77.3 million, with a median of $82.2 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 41.45% in 2021, then fell 11.17% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $61.0 million in 2021, then grew by 23.09% to $75.1 million in 2022, then grew by 23.74% to $92.9 million in 2023, then fell by 10.65% to $83.0 million in 2024, then increased by 1.56% to $84.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $84.3 million in Q3 2025, $82.2 million in Q2 2025, and $83.3 million in Q1 2025.